@article {Albertie660作者= {Paola阿尔贝蒂大卫。p .; 8:32和David r . Cornblath英格马中华民国Merkies和苏珊娜公园和拱形Velasco乔迪布鲁纳和迪米特里Psimaras Susanne Koeppen和安德里亚速度和苏珊·g·多尔西和安德烈亚斯•a . Argyriou Haralabos p Kalofonos Chiara Briani和安吉洛Schenone Catharina g·费伯安娜Mazzeo和沃尔夫冈Grisold MariaGrazia Valsecchi Guido Cavaletti和代表CI-PeriNomS集团},编辑={,滨艾琳娜和Longarini和Cazzaniga Raffaella Guidi,亚历山德罗和Postma, Tjeerd J和戈尔茨坦,大卫和理查德,达米安和法尼,卡米尔和布鲁克斯,DuBose Renn,辛西娅·L和Gali {\ ' e}, Edvina Campagnolo,玛尔塔和卡斯特拉尼,弗兰西斯卡和茅,码头和分公司,罗伊我和外邦人,卢卡和罗威马西莫,Toscano安东尼奥},title ={未来的卫生保健提供者和病人评估评估化疗所致外周神经毒性},体积={97}={7},页面= {e660——e672} = {2021}, doi = {10.1212 / WNL。出版商0000000000012300}= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={背景和目的没有达成协议的黄金标准检测和分级化疗所致的周围神经毒性(CIPN)在首页临床试验中。目标是执行一个观察前瞻性研究来评估和比较基于和CIPN physician-based检测和分级的方法。方法连续患者,18岁以上,候选人毒害神经的化疗,是参加美国、欧盟、澳大利亚。一个训练有素的人员执行physician-based尺度(总神经病变评分{\ textendash}临床[TNSc],用于计算总神经病变评分{\ textendash}护士[TNSn])和监督patient-completed问卷(癌症治疗功能的评估/妇科肿瘤组{\ textendash}神经毒性[事实/ GOG-NTX])。评估之前和结束时进行化疗。参与者没有神经病变在基线,我们评估之间的联系TNSc, / GOG-NTX TNSn,事实。考虑先前建立最小临床重要的区别(MCID) / GOG-NTX,我们确定参与者有或没有一个临床上重要的根据这种规模的恶化。然后,我们计算了MCID TNSc和TNSn均值的差异变化分数的两组之间的尺度。结果来自254个参与者的数据可用:180(71 \ %)正常神经在基线状态。在研究结束时,88 \ %的参与者开发任何等级的神经病变。TNSc TNSn,事实/ GOG-NTX显示良好的响应性(标准化意味着改变从基线到结束化疗\ > 1为所有尺度)。在基线和治疗的153名参与者没有神经病变与一个已知的神经毒性的化疗方案,我们验证了一个温和的相关性TNSc和TNSn分数与事实/ GOG-NTX(斯皮尔曼相关指数r = 0.6)。 On the same sample, considering as clinically important a change in the FACT/GOG-NTX score of at least 3.3 points, the MCID was 3.7 for TNSc and 2.8 for the TNSn.Conclusions MCID for TNSc and TNSn were calculated and the TNSn can be considered a reliable alternative objective clinical assessment if a more extended neurologic examination is not possible. The FACT/GOG-NTX score can be reduced to 7 items and these items correlate well with the TNSc and TNSn.Classification of Evidence This study provides Class III evidence that a patient-completed questionnaire and nurse-assessed scale correlate with a physician-assessed scale.CI=confidence interval; CIPN=chemotherapy-induced peripheral neurotoxicity; CRO=clinician-reported outcome; EORTC=European Organization for Research and Treatment of Cancer; FACT/GOG-NTX=Functional Assessment of Cancer Treatment/Gynecologic Oncology Group{\textendash}Neurotoxicity; MCID=minimal clinically important difference; NCI-CTCAE=National Cancer Institute Common Terminology Criteria for Adverse Events; NCS=nerve conduction studies; PRO=patient-reported outcome; QST=quantitative sensory testing; TNS=Total Neuropathy Score; TNSc=Total Neuropathy Score, clinical version; TNSn=Total Neuropathy Score, nurse-assessed version}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/97/7/e660}, eprint = {//www.ez-admanager.com/content/97/7/e660.full.pdf}, journal = {Neurology} }